All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Psoriasis is a chronic inflammatory condition that affects approximately 2–3% of the global population.1 Psoriasis can occur alongside other conditions, including cardiovascular disease, Crohn’s disease, and psoriatic arthritis.1 Plaque psoriasis is the most common type, accounting for approximately 80–90% of cases.2,3 Other types of psoriasis include guttate, pustular, inverse, and erythrodermic psoriasis.2,3
Psoriasis can have a significant impact on quality of life and is associated with metabolic, cardiovascular, and psychological comorbidities.2,3 In recent years, there have been advances in the understanding of the pathogenesis and genetics of psoriasis, and there have been multiple new biologics approved.
Here, we provide a summary of the etiology, epidemiology, pathophysiology, clinical manifestations, diagnostic tests and tools, and treatment options available for psoriasis.
Etiology2
Psoriasis can be caused by genetic and environmental triggers. Multiple identified alleles have been linked to psoriasis, including HLA-Cw6 and HLADQ*02:01, and loci, including PSORS1–9 and PSORSASI. Around 40% of people will develop psoriasis if both parents are affected. In genetically susceptible individuals, onset of psoriasis can be exacerbated by environmental factors such as skin trauma, infections, medications (including lithium), stress, and smoking. Around one-third of psoriasis patients develop psoriatic arthritis during their lifetime. Moreover, there are several comorbidities associated with psoriasis. These include:
- cardiometabolic disease (e.g., diabetes and stroke);
- psychological illness (e.g., depression and anxiety); and
- inflammatory bowel disease (e.g., Crohn’s disease and ulcerative colitis).
Epidemiology4
Approximately 125 million people worldwide have psoriasis. Studies suggest that psoriasis may be most common in northern Europe and least common in eastern Asia. Global disability burden of the disease tends to increase with age, with the greatest disease burden in individuals aged 50–69 years (Figure 1).
Figure 1. Epidemiology of psoriasis*
PsA, psoriatic arthritis.
*Data from National Psoriasis Foundation.4
Pathophysiology2
The pathophysiology of psoriasis is multifactorial and involves excessive activation of parts of the adaptive immune system, which can be partially due to environmental triggers (Figure 2).
Figure 2. Pathophysiology of psoriasis*
CCL, chemokine ligand; IL, interleukin; ILC, innate lymphoid cell; JAK, Janus kinase; STAT, signal transducers and activators of transcription; TGF, transforming growth factor; Th, T helper; TNF, tumor necrosis factor; TiP-DC, TNF and inducible nitric oxide synthase producing dendritic cell.
*Adapted from Armstong and Read.2 Created with BioRender.com
In the initial stages of psoriasis development, multiple cells including keratinocytes will secrete cytokines which activate myeloid dendritic cells. These cells secrete interleukins, inducing differentiation of naïve T cells to T helper cells. The T helper cells secrete interleukins and tumor necrosis factor alpha, leading to transcription of key inflammatory mediators and keratinocyte proliferation. This results in immune cell infiltration of the skin.
Signs and symptoms
There are multiple types of psoriasis.2 The most common type of psoriasis is plaque psoriasis (also called psoriasis vulgaris).2 Other types of psoriasis are inverse psoriasis, guttate psoriasis, erythrodermic psoriasis, pustular psoriasis, nail psoriasis, and scalp psoriasis.2,5 Signs and symptoms may differ across the types of psoriasis (Figure 3).5,6 Patients can have multiple types of psoriasis at the same time.5
Figure 3. Signs and symptoms of psoriasis*
*Data from Gisondi, et al.6 Created with BioRender.com
Diagnosis
Due to the nature of psoriasis, it can be mistaken for other skin diseases, such as atopic dermatitis, seborrheic dermatitis, and pityriasis rosea.6 Diagnosis of psoriasis includes determining if there is a family history of psoriatic disease, and carrying out skin and nail examinations including morphology.6 The skin examination should be detailed, including the nails, scalp, flexures, and intergluteal cleft, as well as genital areas as patients may be embarrassed to discuss genital involvement.7 Psoriasis can often be diagnosed clinically, but skin biopsies may be required in atypical cases.6 Guidance on diagnosis may vary between countries; see the key guidelines section.
Management
Treatment strategies for psoriasis are based on psoriasis severity, presence of comorbidities, and patient preference and satisfaction.3 Some countries have adopted the concurrent use of biologics, oral agents, and phototherapies for moderate-to-severe plaque psoriasis.3 There is an increase in the treat-to-target approach, which may lead to better control of psoriasis and improved patient outcomes.8
There are many approved treatment options available for psoriasis. An overview of some of the available treatments is provided below (Figure 4).3
Figure 4. Overview of treatments available for psoriasis*
DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, Janus kinase; PDE4, phosphodiesterase-4; STAT, signal transducers and activators of transcription; TNF, tumor necrosis factor; TYK2, tyrosine kinase 2.
*Data from Abdallah, et al.3
- A key drug approval timeline for psoriasis can be found here. Guidance on management may vary between countries; see below.
Key guidelines and organizations
EU guidelines
- EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris
- EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris–Part 2: specific clinical and comorbid situations
US guidelines
UK guidelines
Chinese guidelines
Medical societies/working groups
Patient organizations
- Drakos A, Vender R. A review of the clinical trial landscape in psoriasis: An update for clinicians. Dermatol Ther (Heidelb). 2022;12(12):2715-2730. DOI: 1007/s13555-022-00840-9
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: review. JAMA. 2020;323(19):1945-1960. DOI: 1001/jama.2020.4006
- Ben Abdallah H, Johansen C, Iversen L. Key signaling pathways in psoriasis: Recent insights from antipsoriatic therapeutics. Psoriasis (Auckl). 2021;11:83-97. DOI: 2147/PTT.S294173
- National Psoriasis Foundation. Psoriasis statistics. https://www.psoriasis.org/psoriasis-statistics/ Published Dec 21, 2022. Accessed Jan 29, 2024.
- American Academy of Dermatology Association. Types of psoriasis: Can you have more than one? https://www.aad.org/public/diseases/psoriasis/treatment/could-have/types.
- Gisondi P, Bellinato F, Girolomoni G. Topographic differential diagnosis of chronic plaque psoriasis: challenges and tricks. J Clin Med. 2020;9(11):3594. DOI: 3390/jcm9113594
- Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301-1315. DOI: 10.1016/S0140-6736(20)32549-6
- Noviani M, Feletar M, Nash P, et al. Choosing the right treatment for patients with psoriatic arthritis. Ther Adv Musculoskelet Dis. 2020. Online ahead of print. DOI: 1177/1759720X20962623